Immunome, Inc.

Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s work centers on antibody-drug conjugates and other oncology-focused modalities designed to identify and attack specific disease targets while limiting effects on healthy tissue. Its current portfolio includes late-stage and early-stage programs such as varegacestat for desmoid tumors, IM-1021, and additional investigational assets in radiotherapy and solid-tumor antibody-drug conjugates. Immunome also uses proprietary antibody discovery capabilities to support the identification of novel therapeutic candidates and targets. Based in Bothell, Washington, Immunome operates as a research-driven drug development company serving the oncology market through a pipeline of clinical and preclinical assets.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Clay B. Siegall Ph.D.

Employees

247

Headquarters

Bothell, WA, United States

Website

immunome.com